Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer
- PMID: 11790897
- PMCID: PMC3851093
- DOI: 10.1155/2001/674959
Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer
Abstract
Nipple aspirate fluid (NAF) has been used for many years as a potential non-invasive method to identify markers for breast cancer risk or early detection. Because individual markers have not been optimal, we are exploring the use of surface enhanced laser desorption and ionization time of flight (SELDI-TOF) mass spectrometry to identify patterns of proteins that might define a proteomic signature for breast cancer. SELDI-TOF was used to analyze a study set of NAF samples that included 12 women with breast cancer and 15 healthy controls (the latter included three women with an abnormal mammogram but subsequent normal biopsy). In this preliminary report, we present data showing that SELDI analysis of NAF is rapid, reproducible, and capable of identifying protein signatures that appear to differentiate NAF samples from breast cancer patients and healthy controls, including those with an abnormal mammogram who were later proven to be biopsy normal.
Similar articles
-
Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS.Int J Cancer. 2005 May 1;114(5):791-6. doi: 10.1002/ijc.20742. Int J Cancer. 2005. PMID: 15609313
-
Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid.Clin Cancer Res. 2004 Nov 15;10(22):7500-10. doi: 10.1158/1078-0432.CCR-04-1002. Clin Cancer Res. 2004. PMID: 15569980
-
Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry.Breast Cancer Res Treat. 2005 Jan;89(2):149-57. doi: 10.1007/s10549-004-1710-4. Breast Cancer Res Treat. 2005. PMID: 15692757 Clinical Trial.
-
Protein profile analysis of the breast microenvironment to differentiate healthy women from breast cancer patients.Expert Rev Proteomics. 2009 Feb;6(1):43-60. doi: 10.1586/14789450.6.1.43. Expert Rev Proteomics. 2009. PMID: 19210126 Review.
-
Clinical applications of proteomics: proteomic pattern diagnostics.J Mammary Gland Biol Neoplasia. 2002 Oct;7(4):433-40. doi: 10.1023/a:1024042200521. J Mammary Gland Biol Neoplasia. 2002. PMID: 12882527 Review.
Cited by
-
Use of ProteinChip array surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) to identify thymosin beta-4, a differentially secreted protein from lymphoblastoid cell lines.J Am Soc Mass Spectrom. 2003 Jul;14(7):760-5. doi: 10.1016/s1044-0305(03)00265-4. J Am Soc Mass Spectrom. 2003. PMID: 12837598
-
Proteomics-Based Identification of Dysregulated Proteins in Breast Cancer.Proteomes. 2022 Oct 21;10(4):35. doi: 10.3390/proteomes10040035. Proteomes. 2022. PMID: 36278695 Free PMC article. Review.
-
Reverse phase protein microarrays advance to use in clinical trials.Mol Oncol. 2010 Dec;4(6):461-81. doi: 10.1016/j.molonc.2010.09.003. Epub 2010 Oct 16. Mol Oncol. 2010. PMID: 20974554 Free PMC article. Review.
-
Ductal approaches to assessment and management of women at high risk for developing breast cancer.Breast Cancer Res. 2004;6(2):75-81. doi: 10.1186/bcr759. Epub 2004 Jan 26. Breast Cancer Res. 2004. PMID: 14979910 Free PMC article. Review.
-
The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions.Breast Cancer Res. 2003;5(6):320-8. doi: 10.1186/bcr655. Epub 2003 Oct 9. Breast Cancer Res. 2003. PMID: 14580250 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical